Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment

[1]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[2]  A. Masamune,et al.  Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction , 2013, Front. Physiol..

[3]  M. Vinciguerra,et al.  Sympathetic Nervous System Catecholamines and Neuropeptide Y Neurotransmitters Are Upregulated in Human NAFLD and Modulate the Fibrogenic Function of Hepatic Stellate Cells , 2013, PloS one.

[4]  P. Philip,et al.  Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. , 2013, European journal of cancer.

[5]  J. Kiecolt-Glaser,et al.  Beta‐blockers may reduce intrusive thoughts in newly diagnosed cancer patients , 2013, Psycho-oncology.

[6]  E. Sloan,et al.  Bioluminescent orthotopic model of pancreatic cancer progression. , 2013, Journal of visualized experiments : JoVE.

[7]  W. Frankel,et al.  Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. , 2013, Cancer research.

[8]  S. Pandol,et al.  A starring role for stellate cells in the pancreatic cancer microenvironment. , 2013, Gastroenterology.

[9]  V. Velculescu,et al.  Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors , 2012, Clinical Cancer Research.

[10]  M. Ullah,et al.  Celecoxib and GABA Cooperatively Prevent the Progression of Pancreatic Cancer In Vitro and in Xenograft Models of Stress-Free and Stress-Exposed Mice , 2012, PloS one.

[11]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[12]  R. Pirola,et al.  Pancreatic stellate cells: a starring role in normal and diseased pancreas , 2012, Front. Physio..

[13]  A. Bruzzone,et al.  Involvement of α2‐ and β2‐adrenoceptors on breast cancer cell proliferation and tumour growth regulation , 2012, British journal of pharmacology.

[14]  S. Cole,et al.  Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling , 2012, Brain, Behavior, and Immunity.

[15]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[16]  L. Bujanda,et al.  Mouse models of pancreatic cancer. , 2012, World journal of gastroenterology.

[17]  K. Luo,et al.  Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. , 2012, Hepato-gastroenterology.

[18]  H. Friess,et al.  Nerve-Cancer Interactions in the Stromal Biology of Pancreatic Cancer , 2012, Front. Physio..

[19]  H. Plummer,et al.  Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. , 2012, Carcinogenesis.

[20]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[21]  C. Olsson,et al.  Autonomic control of glands and secretion: A comparative view , 2011, Autonomic Neuroscience.

[22]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[23]  K. Madden,et al.  β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines , 2011, Breast Cancer Research and Treatment.

[24]  H. Schuller.  Beta-adrenergic signaling, a novel target for cancer therapy? , 2010, Oncotarget.

[25]  A. Sood,et al.  The sympathetic nervous system induces a metastatic switch in primary breast cancer. , 2010, Cancer research.

[26]  Heng-tong Hu,et al.  β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1 , 2010, Cancer biology & therapy.

[27]  H. Schuller,et al.  Neurotransmitter receptors as central regulators of pancreatic cancer. , 2010, Future oncology.

[28]  Min Zhang,et al.  Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. , 2009, Oncology reports.

[29]  J. Gaedcke,et al.  The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials , 2009, Langenbeck's Archives of Surgery.

[30]  H. Plummer,et al.  Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. , 2009, Carcinogenesis.

[31]  A. Piccoli,et al.  Recurrence after resection for ductal adenocarcinoma of the pancreas , 1997, World Journal of Surgery.

[32]  H. Friess,et al.  Resection of Primary Pancreatic Cancer and Liver Metastasis: A Systematic Review , 2009, Digestive Surgery.

[33]  H. Reber,et al.  Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. , 2008, Archives of surgery.

[34]  D. Berger,et al.  The role of the tumor microenvironment in the progression of pancreatic cancer. , 2008, The Journal of surgical research.

[35]  David Goldstein,et al.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.

[36]  M. Fiore,et al.  Repeated restraint and nerve growth factor administration in male and female mice: effect on sympathetic and cardiovascular mediators of the stress response. , 2008, Current neurovascular research.

[37]  Jiayuh Lin,et al.  Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane. , 2008, International journal of oncology.

[38]  C. Ko,et al.  National Failure to Operate on Early Stage Pancreatic Cancer , 2007, Annals of surgery.

[39]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Friess,et al.  Surgery for Recurrent Pancreatic Ductal Adenocarcinoma , 2007, Annals of surgery.

[42]  Y. Ogata,et al.  Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings , 2006, Journal of Gastrointestinal Surgery.

[43]  H. Schuller.  Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. , 2007, Progress in experimental tumor research.

[44]  Liz Y. Han,et al.  Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma , 2006, Nature Medicine.

[45]  Jin‐Young Jang,et al.  Analysis of Long-term Survivors After Surgical Resection for Pancreatic Cancer , 2006, Pancreas.

[46]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.

[47]  M. Tsao,et al.  The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through β-adrenergic transactivation of EGF receptors , 2005, Journal of Cancer Research and Clinical Oncology.

[48]  B. Tilton,et al.  Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. , 2005, Molecular and cellular probes.

[49]  Lily Wu,et al.  Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection , 2005, Nature Medicine.

[50]  E. Demidenko,et al.  Mixed Models: Theory and Applications (Wiley Series in Probability and Statistics) , 2004 .

[51]  L. Carlson,et al.  High levels of untreated distress and fatigue in cancer patients , 2004, British Journal of Cancer.

[52]  Y. Ogata,et al.  Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitations , 1995, World Journal of Surgery.

[53]  David A. Padgett,et al.  Experimental Models of Stress and Wound Healing , 2004, World Journal of Surgery.

[54]  H. Buhr,et al.  An Orthotopic Nude Mouse Model for Evaluating Pathophysiology and Therapy of Pancreatic Cancer , 2003, Pancreas.

[55]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[56]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[57]  Steven Piantadosi,et al.  The prevalence of psychological distress by cancer site , 2001, Psycho-oncology.

[58]  Y. Soini,et al.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  D. Ryan,et al.  Prevention of stress-induced weight loss by third ventricle CRF receptor antagonist. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[60]  R. Schilsky,et al.  An investigational new drug treatment program for patients with gemcitabine , 1999, Cancer.

[61]  G. Shakhar,et al.  Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity , 1999, International journal of cancer.

[62]  J. Sheridan,et al.  Stress-induced changes attributable to the sympathetic nervous system during experimental influenza viral infection in DBA/2 inbred mouse strain , 1994, Journal of Neuroimmunology.

[63]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[64]  R. Ader,et al.  Brain, behavior, and immunity , 1987, Brain, Behavior, and Immunity.

[65]  C. A. Richins.  The innervation of the pancreas , 1945, The Journal of comparative neurology.